.jpeg)
{{ variable.name }}
The mechanism of action of cabergoline is derived from the efficient regulation of the hypothalamic-pituitary axis. It can significantly reduce serum prolactin levels and is suitable for the treatment of idiopathic or pituitary adenoma-related hyperprolactinemia.
1. Common name: Cabergoline (Cabergoline)
2. Trade name: Dostinex®
1. Indications: Indicated for the treatment of adult hyperprolactinemia, including elevated prolactin levels caused by idiopathic or pituitary adenomas.
2. Restricted use: It is prohibited to use to inhibit or block postpartum physiological lactation due to the risk of serious adverse reactions.
1. Specifications: Each tablet contains 0.5 mg of cabergoline.
2. Characteristics: White capsule-shaped tablets, with a score on one side, marked with "P" and "U", and "700" engraved on the other side.
1. Active ingredient: Cabergoline 0.5mg.
2. Excipients: Leucine (USP) and lactose (NF).
1. Starting dose: 0.25mg, taken orally twice a week².
2. Dose adjustment: Increase by 0.25mg every 4 weeks (twice a week) until the serum prolactin level returns to normal; the maximum recommended dose is 1mg, twice a week.
3. Monitoring after discontinuation of medication: After discontinuation of medication, serum prolactin levels need to be measured regularly to assess whether treatment needs to be resumed.
1. Before and after meals: It can be taken with food or on an empty stomach. Food does not affect its pharmacokinetics.
2. Missed dose: If you miss a dose, you should take it as soon as possible. If it is close to the next dose time, skip it. Do not double the dose.
3. Vomiting: If you vomit after taking the medicine, you need to judge whether to take more medicine according to the time of vomiting, and consult a doctor if necessary.
4. Others: A cardiac ultrasound examination is required before treatment to rule out valvular disease; during treatment, cardiac ultrasound examination will be reviewed every 6-12 months.
1. Liver insufficiency:
No dose adjustment is required for mild (Child-PughA);
Adverse reaction monitoring is required for moderate (Child-PughB);
Avoid use for severe (Child-PughC).
2. Renal insufficiency: There is no significant change in pharmacokinetics in patients with moderate to severe renal insufficiency, and no dose adjustment is required.
3. Elderly people: Insufficient data, so use with caution.
4. Pregnant women and lactation period:
Pregnant women can only use it when the benefits outweigh the risks, and need to be re-evaluated after discovering pregnancy;
It is contraindicated during lactation and is not used to inhibit lactation.
1. Common adverse reactions (incidence >10%): Nausea (27%), headache (26%), dizziness (15%).
2. Serious adverse reactions:
Heart valve disease and pericardial fibrosis;
Pleural, pulmonary and retroperitoneal fibrosis;
Orthostatic hypotension (incidence 4%);
Impulse control disorders (such as pathological gambling, hypersexuality, compulsive consumption, etc.).
3. Other reported adverse reactions: Constipation, fatigue, abnormal vision, hair loss, mental disorders, etc.
1. Uncontrolled hypertension;
2. Allergy to ergot derivatives;
3. History of heart valve disease or pericardial fibrosis;
4. History of pleural, pulmonary or retroperitoneal fibrosis.
It is prohibited to use this product in combination with dopamine D2 receptor antagonists (such as phenothiazines, butyrophenones, thioxanthenes or metoclopramide).
Store at room temperature (20°C–25°C/68°F–77°F);
Keep in original packaging and keep out of reach of children.